Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 15/20 | 0.59 |
| ▸ | CA12 | O43570 | 11/20 | 0.59 |
| ▸ | CA9 | Q16790 | 10/20 | 0.59 |
| ▸ | CA1 | P00915 | 10/20 | 0.59 |
| ▸ | CA7 | P43166 | 10/20 | 0.59 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | SOS1 | Q07889 | 2/20 | 0.47 |
| ▸ | CA4 | P22748 | 3/20 | 0.46 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.46 |
| ▸ | CA5A | P35218 | 3/20 | 0.45 |
| ▸ | CA5B | Q9Y2D0 | 3/20 | 0.45 |
| ▸ | CA3 | P07451 | 1/20 | 0.45 |
| ▸ | CA6 | P23280 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1104957 | 0.81 | ALDH1A1 (0.39) | CA2CA12CA9CA1CA7 | |
| SCHEMBL1104955 | 0.79 | SMN1; SMN2 (0.59) | CA2CA12CA9CA1CA7 | |
| SCHEMBL1104972 | 0.79 | LMNA (0.59) | ALDH1A1HTTSMN1; SMN2 | |
| SCHEMBL1695070 | 0.78 | ALDH1A1 (0.64) | CA2CA12CA9CA1CA7 | |
| SCHEMBL4706398 | 0.75 | CA2 (1.00) | CA2CA12CA9CA1CA7 | |
| SCHEMBL1104967 | 0.74 | TDP1 (0.52) | TSHRALDH1A1SMN1; SMN2 | |
| SCHEMBL1104968 | 0.73 | TDP1 (0.37) | CA2CA12CA9CA1CA7 | |
| SCHEMBL5595956 | 0.72 | CA1 (1.00) | CA2CA12CA9CA1CA7 | |
| SCHEMBL615392 | 0.72 | CA2 (1.00) | CA2CA12CA9CA1CA7 | |
| SCHEMBL113508 | 0.71 | PTGS2 (0.78) | CA2CA12CA9CA1CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8907101-B2 | Sulfonamide derivatives | PFIZER LIMITED (GB) | 2014-12-09 | — | — | US | disclosed |
| US-8541588-B2 | Sulfonamide derivatives | PFIZER LIMITED (GB) | 2013-09-24 | — | — | US | disclosed |
| US-20120149679-A1 | Sulfonamide Derivatives | ICAGEN, INC. | 2012-06-14 | — | — | US | disclosed |
| US-8153814-B2 | Sulfonamide derivatives | PFIZER LIMITED (GB) | 2012-04-10 | — | — | US | disclosed |
| US-20100197655-A1 | SULFONAMIDE DERIVATIVES | Pfizer Limited Icagen, Inc. | 2010-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197655-A1 | SULFONAMIDE DERIVATIVES | SULT2A1, SULT1A1, TPST2 | CA2 302/4885CA12 1165/4885CA9 1021/4885 |
| US-20120149679-A1 | Sulfonamide Derivatives | SULT2A1, SULT1A1, TPST2 | CA2 302/4885CA12 1165/4885CA9 1021/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.